Form 4: Amgen Executive Murdo Gordon Reports Acquisition of 8,085 Shares of Common Stock
SEC Form 4 Filing
EVP of Global Commercial Operations at Amgen, Murdo Gordon, reports acquiring 8,085 shares of common stock on March 3, 2025.
Summary
- Murdo Gordon, EVP of Global Commercial Operations at Amgen, filed a Form 4 with the SEC.
- The filing reports a transaction that occurred on March 3, 2025.
- Gordon acquired 8,085 shares of Amgen common stock.
- The acquisition price was $0 per share.
- Following the transaction, Gordon beneficially owns 52,271 shares of Amgen common stock.
- The reported shares include 773 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing, so the sentiment is neutral.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to the market.
Stakeholder Impact
- The filing provides transparency to shareholders regarding insider transactions.
Key Dates
| Date | Description |
|---|---|
| 03/03/2025 | Date of transaction: Murdo Gordon acquired 8,085 shares of Amgen common stock. |
| 03/05/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.